Navigation Links
Amgen to Present Pivotal Data From Four Phase 3 Studies at the ECCO 15 - ESMO 34 Congress
Date:9/16/2009

THOUSAND OAKS, Calif., Sept. 16 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced it will present detailed data from four Phase 3 studies as well as other data at the ECCO 15 - ESMO 34 European Multidisciplinary Congress, September 20 - 24, 2009 in Berlin, Germany.

Researchers will present data from two Phase 3 head-to-head studies evaluating denosumab versus Zometa(R) (zoledronic acid) for the treatment of bone metastases in patients with advanced breast cancer (the '136' study) and the treatment of bone metastases in advanced cancer patients with solid tumors (not including breast and prostate cancer) or multiple myeloma (the '244' study).

Detailed data will also be presented from two Phase 3 studies evaluating Vectibix(R) (panitumumab) in combination with chemotherapy for the first-line and second-line treatment of metastatic colorectal cancer (the '203' and '181' trials, respectively).

"Amgen is very pleased to be presenting these important data from the denosumab and Vectibix development programs," said Roger M. Perlmutter, M.D., Ph.D., executive vice president of Research and Development at Amgen. "The data from these trials demonstrate that both denosumab and Vectibix have the potential to improve outcomes in patients suffering from cancer."

SELECTED ABSTRACTS OF INTEREST

Identified below are selected abstracts of interest on Amgen research. Updated data will be presented at the meeting.

    Denosumab
    --  A double-blind, randomized study of denosumab versus zoledronic acid
    for the treatment of bone metastases in patients with advanced cancer
    (excluding breast and prostate cancer) or multiple myeloma
        Lead Author: Henry, D.
        Abstract No. 20L
'/>"/>
SOURCE Amgen
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
2. InteKrin Therapeutics, Inc. Appoints Former Amgen Clinical Development Executive Chief Medical Officer
3. OmniPod(R) Insulin Management System Lets Team Type 1 Members Focus on Competing at Amgen Tour of California
4. Amgen to Present at the Barclays Capital Global Healthcare Conference
5. Amgen Announces Webcast of 2009 First Quarter Financial Results
6. Amgens First Quarter 2009 Adjusted Earnings Per Share Decreased 4 Percent to $1.08
7. Amgen and ONSEdge Partner With Cancer Survivor Jan Ping for New Campaign
8. Amgen to Present at the Deutsche Bank 34th Annual Healthcare Conference
9. Amgen Highlights Data to Be Presented at ASCO
10. Amgens Denosumab and Eli Lillys Forteo/Forsteo Will Drive Robust Annual Growth in the Osteoporosis Drug Market From 2013 to 2018
11. Loyola fellow receives Amgen grant to study treatments for older leukemia patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... combining salmon fibrin injections into the spinal cord and ... voluntary motor function impaired by spinal cord injury, scientists ... In a study on rodents, Gail Lewandowski and Oswald ... clock in a molecular pathway critical to the formation ... so that neuronal axons at the injury site could ...
(Date:7/23/2014)... 2014 This report defines and segments ... Europe, the Middle East & Africa, and Americas) - ... geography with analysis and forecasts of the global revenue. ... from over $10 billion in 2014 to nearly $14 ... , browse 49 Market Tables and 10 Figures ...
(Date:7/23/2014)... A Forever Recovery, an open-ended drug ... a great start and gives them a solid foundation ... new Internet Addiction section of its website at ... that Internet addiction is not just as legitimate a ... it’s trapping more and more victims each year – ...
(Date:7/23/2014)... -- Children and teens who lose a parent might face ... new study suggests. People who were children or teens ... of death during the study period than those who had ... report. Although the study found an association between a ... it wasn,t designed to prove cause-and-effect. Also, the increased ...
(Date:7/23/2014)... 2014 SafeUseNow? , a ... developed by Principled Strategies , today announced ... California . Utilizing SafeUseNow’s patent-pending risk model, Partnership ... misusing and abusing controlled substance drugs, particularly prescription ... its members. , The agreement with Partnership HealthPlan ...
Breaking Medicine News(10 mins):Health News:Gene inhibitor, salmon fibrin restore function lost in spinal cord injury 2Health News:EHV Transmission Market $14 Billion by 2019 - Report by MarketsandMarkets 2Health News:EHV Transmission Market $14 Billion by 2019 - Report by MarketsandMarkets 3Health News:EHV Transmission Market $14 Billion by 2019 - Report by MarketsandMarkets 4Health News:Latest A Forever Recovery Launches Internet Addiction Section on Website 2Health News:Parent's Death May Raise Risk of Early Death for Grown Children, Study Suggests 2Health News:Partnership HealthPlan of California Signs Program Participation Agreement with SafeUseNow 2Health News:Partnership HealthPlan of California Signs Program Participation Agreement with SafeUseNow 3Health News:Partnership HealthPlan of California Signs Program Participation Agreement with SafeUseNow 4
... artists like Ram Kumar, V S Gaitonde and Jehangir ... of contemporary Indian paintings and sculptures held at Durban ... // ,Since having a cultural co-operation between Indian ... between the gallery like Iziko South African National Gallery ...
... painstaking and reaps benefits only when done with full dedication. ... in Georgetown. This has brought to the world the first cancer ... when on June 8, the Food and Drug Administration approved the ... of HPV. ,In the doctor’s own words, "It's a ...
... colleagues at the Indiana University Medical Center, Indianapolis say ... into having unwanted sex //. ,Unwanted sex ... researchers write in the June issue of the Archives ... result in risk for sexually transmitted infections and pregnancies. ...
... inputs on the manner of T-cells enabling immunity and furthering ... will go a long way in measuring the efficiency of ... ,Led by researchers at Beth Israel Deaconess Medical ... National Institute of Allergy and Infectious Diseases (NIAID), part of ...
... leader Sri Sri Ravishankar has said practising yoga, pranayam and ... alcohol abuse. // ,'Youths crave for something different ... dhyan (meditation) to them,' he said while interacting with reporters ... Kundaim, 15 km from here., ,Ravi Shankar appealed to ...
... that secondhand smoking can be deadly. Hence California and Washington laws ... was 58 years old physically fit suffered from heart problems that ... he worked in smoky taverns for 37 years. So the doctors ... to find that the indoor air pollution levels in bars that ...
Cached Medicine News:Health News:Research on AIDS vaccine a wealth of information 2Health News:Research on AIDS vaccine a wealth of information 3
(Date:7/23/2014)... -- The management team at Columbia Laboratories, Inc. (Nasdaq: ... call on July 31, 2014, to discuss financial ... 2014.  The call details are as follows:Date: , ... numbers: , Toll free: (877) 870-4263 (U.S.), (855) ... , www.columbialabs.com , under ,Investor, or ...
(Date:7/23/2014)... SUNNYVALE, Calif. , July 23, 2014 /PRNewswire/ ... devices for the transcarotid treatment of intra- and ... Michael P. Wallace to the position ... Michael will lead the company,s Research and Development ... treatment devices. Prior to joining ...
(Date:7/23/2014)... July 23, 2014  Dompe, a leader in R&D for ... that rhNGF (Recombinant Human Nerve Growth Factor) has been designated ... Administration (FDA). The candidate drug, developed by ... drug for the treatment of neurotrophic keratitis, a degenerative corneal ... and is currently without a cure. This is the ...
Breaking Medicine Technology:Columbia Laboratories to Discuss Second Quarter 2014 Financial Results on July 31st Conference Call 2Silk Road Medical Appoints Ground Breaking Innovator as Chief Technology Officer 2Silk Road Medical Appoints Ground Breaking Innovator as Chief Technology Officer 3Dompe announces the Food and Drug Administration (FDA) has granted orphan drug designation to its rhNGF-based treatment for neurotrophic keratitis 2Dompe announces the Food and Drug Administration (FDA) has granted orphan drug designation to its rhNGF-based treatment for neurotrophic keratitis 3Dompe announces the Food and Drug Administration (FDA) has granted orphan drug designation to its rhNGF-based treatment for neurotrophic keratitis 4
... DIEGO, April 20, 2012 /PRNewswire-iReach/ -- Nutrilys ... San Diego, has partnered with the Los Angeles Police ... armor. Nutrilys Del Mar founder, Thierry Lerond, journeyed to Los ... while helping them handpick the world,s best organic, ...
... 2012  Thoratec Corporation (NASDAQ: THOR ), a ... save, support and restore failing hearts, today announced that ... quarter of fiscal year 2012 on Tuesday, May 1. ... to discuss its financial results and operating activities, open ...
Cached Medicine Technology:Nutrilys Del Mar Joins Health Forces With LAPD Underwater Dive Unit 2Thoratec Schedules First Quarter Conference Call, Webcast 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: